NORAD and breast cancer: MiR-28-3p directly targets transcription factor E2F2, a well-known oncogene associated with poor survival in several cancer types such as breast cancer, ovarian cancer, retinoblastoma, and NORAD-mediated downregulation of the microRNA promote overexpression of the oncogenic transcription factor, leading to increased tumour growth and metastasis (Mao et al., 2022).